Atara Biotherapeutics (NASDAQ:ATRA) Price Target Cut to $4.00 by Analysts at The Goldman Sachs Group

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) had its price target cut by investment analysts at The Goldman Sachs Group from $5.00 to $4.00 in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. The firm currently has a “sell” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price points to a potential downside of 15.43% from the company’s previous close.

A number of other brokerages have also recently issued reports on ATRA. Citigroup cut shares of Atara Biotherapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $15.00 to $8.00 in a report on Monday, May 9th. Canaccord Genuity Group lowered their price objective on shares of Atara Biotherapeutics from $78.00 to $67.00 in a research report on Tuesday, March 1st. JPMorgan Chase & Co. reduced their target price on Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a report on Monday, March 28th. HC Wainwright dropped their target price on shares of Atara Biotherapeutics from $31.00 to $29.00 and set a “buy” rating on the stock in a report on Monday. Finally, StockNews.com cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Atara Biotherapeutics has a consensus rating of “Hold” and a consensus target price of $26.88.

Shares of ATRA stock traded down $0.25 during trading hours on Tuesday, reaching $4.73. The company had a trading volume of 11,720 shares, compared to its average volume of 1,021,681. Atara Biotherapeutics has a 1-year low of $4.70 and a 1-year high of $20.04. The firm has a market cap of $441.81 million, a price-to-earnings ratio of -1.31 and a beta of 1.92. The company has a 50 day moving average of $7.71 and a 200 day moving average of $12.54.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last released its earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.11. Atara Biotherapeutics had a negative return on equity of 122.18% and a negative net margin of 1,451.79%. During the same period last year, the business earned ($0.86) EPS. On average, equities analysts predict that Atara Biotherapeutics will post -3.45 earnings per share for the current fiscal year.

In related news, CFO Utpal Koppikar sold 5,582 shares of the firm’s stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $5.32, for a total transaction of $29,696.24. Following the transaction, the chief financial officer now directly owns 207,592 shares of the company’s stock, valued at $1,104,389.44. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Pascal Touchon sold 13,913 shares of the firm’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $5.32, for a total value of $74,017.16. Following the transaction, the chief executive officer now owns 486,313 shares in the company, valued at approximately $2,587,185.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,591 shares of company stock worth $141,464. Company insiders own 3.80% of the company’s stock.

Large investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale grew its position in shares of Atara Biotherapeutics by 2.9% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 28,400 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 800 shares during the last quarter. Rockefeller Capital Management L.P. lifted its stake in shares of Atara Biotherapeutics by 2.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 38,916 shares of the biotechnology company’s stock worth $613,000 after acquiring an additional 916 shares during the period. Cubist Systematic Strategies LLC increased its position in Atara Biotherapeutics by 7.3% during the 4th quarter. Cubist Systematic Strategies LLC now owns 18,823 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,277 shares during the period. Teacher Retirement System of Texas raised its holdings in Atara Biotherapeutics by 12.6% during the 1st quarter. Teacher Retirement System of Texas now owns 15,447 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 1,728 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in shares of Atara Biotherapeutics by 8.4% during the 1st quarter. Royal Bank of Canada now owns 25,962 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 2,017 shares in the last quarter.

About Atara Biotherapeutics (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

See Also

Stock Target Advisor logo

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.